Introduction {#section5-2050312117729920}
============

Double-balloon enteroscopy (DBE), developed by Yamamoto and colleagues,^[@bibr1-2050312117729920],[@bibr2-2050312117729920]^ enables the observation of the entire small-bowel and intervention such as biopsies, hemostasis, balloon dilatation, and/or polypectomy. However, DBE can be uncomfortable and time-consuming, and patients who undergo the procedure usually require sedatives and analgesics.^[@bibr3-2050312117729920]^ Midazolam (MDZ) or propofol is usually used for sedation during DBE, but these two agents tend to suppress respiration or blood pressure. Moreover, an analgesic is often needed during DBE which may induce further hypotension and respiratory depression. Restlessness or marked body movement during sedation with these agents hampers endoscopic interventions, which we also experienced during DBE.^[@bibr4-2050312117729920]^ Dexmedetomidine (DEX), an α2-adrenergic agonist, acts as a sedative by inhibiting the firing of the locus ceruleus of the brain stem and as an analgesic by inhibiting norepinephrine release at the neuroeffector junction.^[@bibr5-2050312117729920]^ Furthermore, DEX facilitates conscious sedation of patients and maintains stable respiration and circulation. Several randomized controlled trials have evaluated the efficacy of DEX in comparison with MDZ for gastrointestinal endoscopy, especially endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic submucosal dissection (ESD).^[@bibr4-2050312117729920],[@bibr6-2050312117729920][@bibr7-2050312117729920][@bibr8-2050312117729920][@bibr9-2050312117729920]--[@bibr10-2050312117729920]^ However, there are no reports on the use of DEX in DBE. Therefore, the aim of our study was to prospectively evaluate the efficacy and safety of sedation with DEX in DBE.

Methods {#section6-2050312117729920}
=======

Study design {#section7-2050312117729920}
------------

First, consecutive patients who were scheduled for DBE with DEX sedation from July 1 to December 31, 2015, and who provided written consent were prospectively enrolled in the first part of this study. The exclusion criteria were (1) age ≤20 years and (2) serious organ disorder (i.e. heart failure (NYHA (New York Heart Association) classification grade 4), respiratory failure (Fletcher--Hugh--Jones classification grade 5), and hepatic failure (Child--Pugh classification grade C)). This part of the study included 84 patients (118 DBEs) (DEX group). However, three patients (seven DBEs) were excluded because the same insertion route was used during the second time, overtube was not used, insertion from stoma, and lack of records. Finally, 81 patients (111 DBEs) were enrolled.

Second, we retrospectively investigated the adverse events in patients who were sedated with MDZ (MDZ group). We compared the frequency of adverse events between the MDZ and the DEX groups using propensity score matching. For the patients in the second part of this study, we analyzed data of 136 patients who underwent 193 DBEs with MDZ and pentazocine sedation from January 1 to October 31, 2014, in our hospital. In total, 27 DBEs (24 patients) were excluded because they did not have a sedation record or only observation of the colon was performed; 166 DBEs (112 patients) remained.

This study was approved by the ethics committee of participating institution and was registered with a registry approved by the International Committee of Medical Journal Editors (UMIN ID000015785).

Study protocol and monitoring {#section8-2050312117729920}
-----------------------------

All DBEs were carried out using either of the two types of DBE system, the diagnostic type (EN-450P, EN-580XP) and the therapeutic type (EN-450T, EN-580T) (Fujifilm, Tokyo, Japan), with CO~2~ insufflation. CO~2~ insufflation was used in All DBEs.

In the MDZ group, MDZ 0.02 mg/kg was injected intravenously for induction. Sedation was kept at levels 3--5 of the Ramsay Sedation Scale (RSS), which is equivalent to moderate sedation ([Table 1](#table1-2050312117729920){ref-type="table"}).^[@bibr11-2050312117729920]^ MDZ 0.02 mg/kg or pentazocine 15 mg was additionally injected intravenously during restlessness, body movement, or awaking.

###### 

Ramsey Sedation Scale.

![](10.1177_2050312117729920-table1)

  Score   Response
  ------- --------------------------------------------------------------------
  1       Anxious, agitated, restless
  2       Cooperative, oriented, tranquil
  3       Responsive to commands only
  4       Brisk response to light glabellar tap or loud auditory stimulus
  5       Sluggish response to light glabellar tap or loud auditory stimulus
  6       No response to light glabellar tap or loud auditory stimulus

In the DEX group, patients were sedated with DEX using a loading dose of 6 μg/kg/h over 10 min followed by 0.4-μg/kg/h infusion until the bispectral index (BIS) on the electroencephalogram (EEG) reached 60--80, which is equivalent to moderate sedation. An additional pentazocine dose of 15 mg was given at the beginning of DBE. When needed, 1 mg MDZ, 7.5 or 15 mg pentazocine, or DEX dose adjustment was given.

The blood pressure, heart rate, oxygen saturation, and electrocardiogram were monitored during DBE. Blood pressure was measured every 2.5 min. In addition, BIS and body movements were recorded in the DEX group. Body movements were scored based on the responses described in [Table 2](#table2-2050312117729920){ref-type="table"}.^[@bibr12-2050312117729920],[@bibr13-2050312117729920]^

###### 

Score of body movement.

![](10.1177_2050312117729920-table2)

  Score   Response
  ------- ---------------------------------------------
  1       No movement
  2       Occasional, slight movement
  3       Frequent, slight movement
  4       Vigorous movement limited to extremities
  5       Vigorous movement, including torso and head

Propensity score matching {#section9-2050312117729920}
-------------------------

To compare sedation between the DEX and the MDZ groups, we obtained two subsets from each group using propensity score matching. The propensity scores were estimated using a logistic regression model that included the following 10 covariates: age, sex, body mass index, ASA (American Society of Anesthesiologists) physical status (≤2 and ≥3), surgical history, indication, heart disease (none, NYHA \<3, and NYHA ≥3), respiratory diseases (none, Hugh--Jones ≤3, and Hugh--Jones ≥4), insertion route, and type of endoscope. Based on the propensity score for receiving DEX, patients who received DEX and those who received MDZ were matched on a 1:1 basis.

Patients' and endoscopists' assessment {#section10-2050312117729920}
--------------------------------------

After examination, we handed questionnaires to the patients and collected them on the next day. Both patients and endoscopists evaluated the state of sedation during DBE using a 5-point Likert scale (1, unacceptable; 2, not so good; 3, fair; 4, enough; 5, excellent).

Definition {#section11-2050312117729920}
----------

Hypotension is defined as a decrease in systolic blood pressure ≥30% from baseline and systolic blood pressure \<80 mmHg; respiratory depression is defined as percutaneous oxygen saturation level \<90%; bradycardia is defined as decrease in heart rate ≥30% from baseline and \<40 beats/min.

In both groups, body motion was considered present if body restraint was required for violent body movement, that is, level 4 or 5 in the movement scale.

Statistical analyses {#section12-2050312117729920}
--------------------

Continuous data were compared using the Mann--Whitney test. Categorical variables were tested using the corrected χ^2^ test or Fisher's exact test, as appropriate. Multivariate analysis was performed using multiple logistic analyses. A p-value \<0.05 was used to indicate statistical significance. All statistical analyses without propensity score were performed with the SPSS software (Statistical Package for Social Science, IBM SPSS Statistics, version 23 for Windows; IBM, Armonk, NY, USA). Propensity score matching was performed with JMP, version 11 (SAS Institute, Cary, NC, USA).

Ethical approval {#section13-2050312117729920}
----------------

This study was approved by the ethics committee of our hospital. Written informed consent was obtained from all patients before DBE.

Results {#section14-2050312117729920}
=======

Patient and examination characteristics {#section15-2050312117729920}
---------------------------------------

The patient and examination characteristics, and adverse events in DBE are summarized in [Tables 3](#table3-2050312117729920){ref-type="table"} and [4](#table4-2050312117729920){ref-type="table"}. All patients were Japanese.

###### 

Patient characteristics in MDZ group and DEX group before propensity score matching.

![](10.1177_2050312117729920-table3)

                                MDZ group     DEX group
  ----------------------------- ------------- -------------
  N                             112           81
  Age (years)                   53.4 ± 18.7   52.9 ± 16.6
  Sex                                         
   Male                         74            53
   Female                       38            28
  Height (cm)                   163.6 ± 9.9   165.1 ± 9.3
  Weight (kg)                   56.2 ± 12.1   57.2 ± 12.0
  BMI                           20.9 ± 3.6    20.9 ± 3.4
  ASA-PS                                      
   ≥3                           10 (8.9%)     12 (14.8%)
   ≤2                           102 (91.1%)   69 (85.2%)
  Heart diseases                10 (8.9%)     7 (8.6%)
   NYHA ≥3                      0             2 (2.5%)
  Respiratory diseases          4 (3.6%)      12 (14.8%)
   Hugh--Jones ≥4               0             1 (1.2%)
  History of surgery            62 (55.3%)    41 (50.6%)
  Chronic renal failure         6 (5.4%)      4 (4.9%)
  Chronic liver failure         1 (0.9%)      2 (2.5%)
  Sleeping pills                13 (11.6%)    14 (17.3%)
  Drinking history              Unknown       29 (35.8%)
  Smoking history               Unknown       26 (32.1%)
  Reasons of examinations                     
   Crohn's disease              52 (46.4%)    31 (38.3%)
   Other IBD or suspected       16 (14.3%)    23 (28.4%)
   Tumor or suspected           21(18.8%)     20(17.9%)
   OGIB without tumor and IBD   20 (17.8%)    6 (7.4%)
   Others                       3 (2.3%)      1 (1.2%)

MDZ: midazolam; DEX: dexmedetomidine; BMI: body mass index; ASA-PS: American Society of Anesthesiologists--physical status; NYHA: New York Heart Association; IBD: inflammatory bowel disease; OGIB: obscure gastrointestinal bleeding.

###### 

Examination characteristics in MDZ group and DEX group before propensity score matching.
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                                        MDZ group     DEX group
  ------------------------------------- ------------- -------------
  N                                     166           111
  Insertion route                                     
   Peroral                              68 (41.0%)    56 (50.5%)
   Transanal                            98 (59.0%)    55 (49.5%)
  Endoscopes                                          
   Therapeutic (EN-450T, 580T)          111 (66.9%)   87 (78.4%)
   Diagnostic (EN-450P, 580XP)          55 (33.1%)    24 (21.6%)
  Duration of insertion (min)           42.6 ± 21.8   45.5 ± 20.0
  Total duration of examination (min)   63.2 ± 23.3   68.4 ± 25.6
  Polypectomy                           6 (3.6%)      8 (7.2%)
  Hemostasis                            15 (9.0%)     3 (2.7%)
  Endoscopic balloon dilation           10 (6.0%)     3 (2.7%)
  Endoscopic ultrasound                 3 (1.8%)      7 (6.3%)
  DEX (mg/kg)                                         1.64 ± 0.4
  MDZ (mg)                              15.6 ± 5.8    3.5 ± 2.4
  Pentazocine (mg)                      16.4 ± 7.3    26.5 ± 15.8
  Body motion                           46 (27.7%)    13 (11.7%)
  Hypotension                           7 (1.2%)      13 (11.7%)
  Respiratory depression                128 (77.1%)   55 (49.5%)
  Bradycardia                           6 (3.6%)      2 (1.8%)

MDZ: midazolam; DEX: dexmedetomidine.

Adverse events {#section16-2050312117729920}
--------------

In the MDZ group, of 166 DBEs, 46 (27.7%) had body motion; 7 (1.2%), hypotension; 128 (77.1%), respiratory depression; and 6 (3.6%), bradycardia. There were three perforations, one pancreatitis, one bleeding, and one aspiration pneumonia.

In the DEX group, of 111 DBEs, 13 (11.7%) had body motions and 13 (11.7%) had hypotension. In 55 cases (49.5%), nasal oxygen was given due to decrease in SpO~2~ level, but no intubation was required. Bradycardia was seen in two cases (1.8%). Body motions were seen especially in peroral DBE. Eight (61.5%) of 13 were due to gag reflex during endoscope insertion. There were one pancreatitis and one aspiration pneumonia. The adverse events in each group are shown in [Table 5](#table5-2050312117729920){ref-type="table"}.

###### 

Adverse events in MDZ group and DEX group before propensity score matching.
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                           MDZ group     DEX group
  ------------------------ ------------- ------------
  Body motion              46 (27.7%)    13 (11.7%)
  Hypotension              7 (1.2%)      13 (11.7%)
  Respiratory depression   128 (77.1%)   55 (49.5%)
  Bradycardia              6 (3.6%)      2 (1.8%)
  Perforation              3 (1.8%)      0
  Pancreatitis             1 (0.6%)      1 (0.9%)
  Bleeding                 1 (0.6%)      0
  Aspiration pneumonia     1 (0.6%)      1 (0.9%)

MDZ: midazolam; DEX: dexmedetomidine.

Propensity score matching {#section17-2050312117729920}
-------------------------

After propensity score matching, 182 cases (91 for each group) were selected. The patient and examination characteristics after propensity score matching are summarized in [Tables 6](#table6-2050312117729920){ref-type="table"} and [7](#table7-2050312117729920){ref-type="table"}, respectively. In the DEX group, there was less body motion and less respiratory depression. Hypotension and bradycardia were not significantly different in the two groups ([Table 8](#table8-2050312117729920){ref-type="table"}).

###### 

Patient characteristics in MDZ group and DEX group after propensity score matching.
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                                MDZ group     DEX group     p-value
  ----------------------------- ------------- ------------- ---------
  N                             91            91            
  Age (years)                   48.9 ± 17.9   51.7 ± 17.2   0.405
  Sex                                                       
   Male                         65 (71.4%)    62 (68.1%)    0.628
   Female                       26 (28.6%)    29 (31.9%)    
  Height (cm)                   164.5 ± 9.5   165.2 ± 9.2   0.672
  Weight (kg)                   55.9 ± 12.4   56.4 ± 11.1   0.512
  BMI                           20.6±3.5      20.6±3.2      0.276
  ASA-PS                                                    
   ≥3                           11 (12.1%)    10 (11.0%)    0.817
   ≤2                           80 (87.9%)    81 (89.0%)    
  Heart diseases                8 (8.8%)      6 (6.6%)      0.578
   NYHA ≥3                      0             0             --
   Hypertension                 17 (18.7%)    21 (23.1%)    0.466
  Respiratory diseases          4 (4.4%)      14 (15.4%)    0.013
   Hugh--Jones ≥4               0             0             --
  Chronic renal failure         7 (7.7%)      4 (4.4%)      0.193
  Chronic liver failure         0             2 (2.2%)      0.497
  History of surgery            54 (59.3%)    55 (60.4%)    0.880
  Sleeping pills                8 (8.8%)      10 (11.0%)    0.619
  Indications                                               
   Crohn's disease              38 (41.8%)    43 (47.3%)    0.822
   IBD or suspected             21 (23.1%)    20 (22.0%)    
   Tumor or suspected           27 (29.7%)    21 (23.1%)    
   OGIB without tumor and IBD   4 (4.4%)      5 (5.5%)      
   Others                       1 (1.1%)      2 (2.2%)      

MDZ: midazolam; DEX: dexmedetomidine; BMI: body mass index; ASA-PS: American Society of Anesthesiologists--physical status; NYHA: New York Heart Association; IBD: inflammatory bowel disease; OGIB: obscure gastrointestinal bleeding.

###### 

Examination characteristics in MDZ group and DEX group after propensity score matching.
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                                        MDZ group     DEX group     p-value
  ------------------------------------- ------------- ------------- ---------
  N                                     91            91            
  Insertion route                                                   
   Peroral                              45 (49.5%)    45 (49.5%)    1.000
   Transanal                            46 (50.5%)    46 (50.5%)    
  Scopes                                                            
   Therapeutic (EN-450T, 580T)          70 (76.9%)    71 (78.0%)    0.859
   Diagnostic (EN-450P, 580XP)          21 (23.1%)    20 (22.0%)    
  Polypectomy                           4 (4.4%)      8 (8.8%)      0.232
  Hemostasis                            5 (5.5%)      2 (2.2%)      0.444
  Endoscopic balloon dilation           7 (7.7%)      3 (3.3%)      0.193
  Endoscopic ultrasound                 3 (3.3%)      7 (7.7%)      0.193
  Duration of insertion (min)           45.7 ± 24.8   44.1 ± 19.0   0.871
  Total duration of examination (min)   66.5 ± 24.1   67.6 ± 25.9   0.678
  MDZ (mg)                              17.7 ± 5.8    3.4 ± 2.5     \<0.001
  Pentazocine (mg)                      17.3 ± 7.0    25.7 ± 15.7   \<0.001

MDZ: midazolam; DEX: dexmedetomidine.

###### 

Comparison of adverse events in MDZ group and DEX group after propensity score matching.
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                           MDZ group    DEX group    p-value
  ------------------------ ------------ ------------ ---------
  Body motion              31 (34.1%)   11 (12.1%)   0.001
  Hypotension              4 (4.4%)     8 (8.8%)     0.232
  Respiratory depression   62 (68.1%)   46 (50.5%)   0.023
  Bradycardia              0            2 (2.2%)     0.497
  Perforation              1 (1.1%)     0            1.000
  Pancreatitis             1 (1.1%)     0            1.000
  Bleeding                 1 (1.1%)     0            1.000
  Aspiration pneumonia     0            0            

MDZ: midazolam; DEX: dexmedetomidine.

Assessment of sedation {#section18-2050312117729920}
----------------------

Most of the patients and endoscopists considered the state of sedation as satisfactory, but 16 (18%) patients rated it as unsatisfactory ([Table 9](#table9-2050312117729920){ref-type="table"}). The patients' scores were lower in those who had a recollection of the procedure (p \< 0.001) ([Table 10](#table10-2050312117729920){ref-type="table"}). The significant factors associated with endoscopists' scores were histories of surgery (p = 0.042) and scale of body movement during DBE (p = 0.018) ([Table 11](#table11-2050312117729920){ref-type="table"}).

###### 

Assessment of sedation using a 5-point Likert scale.
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               From patients   From doctors
  ------------ --------------- --------------
  5            22              25
  4            37              56
  3            16              21
  2            14              9
  1            2               0
  Unanswered   20              0
  Mean ± SD    3.69 ± 1.07     3.87 ± 0.85

###### 

Analysis of patients' satisfaction for sedation in DEX group.
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                            Single analysis   Multivariate analysis                                          
  ------------------------- ----------------- ----------------------- --------- ---------------------------- ---------
  Age (years)               52.6 ± 17.5       54.9 ± 17.6             0.700                                  
  Sex (male:female)         45:30             15:1                    0.009     10.038 (0.634--1.841)        0.061
  BMI                       20.6 ± 3.3        20.2 ± 4.2              0.684                                  
  Peroral/transanal         38:37             11:5                    0.188                                  
  Therapeutic/diagnostic    57:18             12:4                    1.000                                  
  ASA-PS ≥3/≤2              10:65             2:14                    1.000                                  
  Drinking history          23:52             9:7                     0.052     5.505 (0.806--37.609)        0.082
  Smoking history           24:51             8:8                     0.171                                  
  Sleeping pills            12:63             5:11                    0.169                                  
  Surgical history          43:32             6:10                    0.149                                  
  Total duration of exam.   69.0 ± 26.1       68.7 ± 29.0             0.650                                  
  DEX                       1.7 ± 0.4         1.7 ± 0.5               0.639                                  
  MDZ                       3.8 ± 2.6         2.5 ± 1.2               0.054     0.925 (0.543--1.577)         0.776
  Pentazocine               29.8 ± 16.7       23.9 ± 14.3             0.165                                  
  Memory while exam.        13:62             15:1                    \<0.001   129.646 (10.640--1579.714)   \<0.001

MDZ: midazolam; DEX: dexmedetomidine; BMI: body mass index; CI: confidence interval.

###### 

Analysis of doctors' satisfaction for sedation in DEX group.
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                            Single analysis   Multivariate analysis                                   
  ------------------------- ----------------- ----------------------- ------- ----------------------- -------
  Age (years)               52.8 ± 17.6       49.1 ± 12.5             0.563                           
  Sex (male:female)         68:34             6:3                     1.000                           
  BMI                       20.8 ± 3.5        20.3 ± 2.7              0.863                           
  Peroral/transanal         51:51             5:4                     1.000                           
  Therapeutic/diagnostic    79:23             8:1                     0.681                           
  ASA-PS ≥3/≤2              15:87             0:9                     0.606                           
  Drinking history          36:66             5:4                     0.286                           
  Smoking history           34:68             1:8                     0.268                           
  Sleeping pills            19:83             1:8                     1                               
  Surgical history          49:53             8:1                     0.032   9.569 (1.083--84.553)   0.042
  Total duration of exam.   68.9 ± 26.4       63.0 ± 17.1             0.51                            
  DEX                       23.8 ± 8.0        21.4 ± 4.2              0.45                            
  MDZ                       3.4 ± 2.4         4.7 ± 2.8               0.148   1.085 (0.838--1.404)    0.536
  Pentazocine               26.9 ± 16.3       21.4 ± 4.2              0.476                           
  Scale of body movement    2 (1--5)          3 (2--5)                0.006   2.455 (1.212--4.971)    0.013

MDZ: midazolam; DEX: dexmedetomidine; BMI: body mass index; CI: confidence interval.

Discussion {#section19-2050312117729920}
==========

The sedative action of DEX, which is an α2-adrenergic agonist, is through the inhibition of firing of the locus ceruleus of the brain stem, whereas MDZ and propofol are γ-aminobutyric acid (GABA) receptor agonist medications in central nerves system. This unique sedative activity is thus unlikely to cause restlessness or respiratory suppression such as that seen with GABA receptor agonists; however, excessive use of DEX has been reported to cause hypotension and bradycardia.^[@bibr14-2050312117729920]^ Although DEX cannot be used for bolus injection, when more rapid deep sedation is needed, another sedative such as MDZ and propofol are needed.

In this study, there were significantly less body motion and respiratory depression in the DEX group than in the MDZ group, but hypotension and bradycardia were not significantly different in the two groups. We used body motion as the primary endpoint because it might cause severe adverse events such as perforations. In fact, three patients in the MDZ group who had perforations had violent body motions during DBE. Therefore, sedation using DEX can contribute to a safer DBE procedure with reduction in body motion and respiratory depression.

In our hospital, the average MDZ dose in the MDZ group was 15.6 ± 5.8 mg, which was higher than that used in another study.^[@bibr15-2050312117729920]^ Among the patients who underwent DBE in our hospital, around 40% had CD, more than half had a history of surgery, and the median age was 52 years ([Table 2](#table2-2050312117729920){ref-type="table"}). However, in the study of Möschler et al.,^[@bibr15-2050312117729920]^ most of the patients had suspected obscure gastrointestinal bleeding (OGIB), 11% had a history of surgery, and the median age was 64 years. MDZ clearance decreased with increasing age.^[@bibr16-2050312117729920]^ Insertion of DBE was significantly influenced by a history of abdominopelvic surgery.^[@bibr17-2050312117729920]^ These might affect the MDZ dose.

We used moderate-to-deep sedation during peroral and transanal DBEs, but opinions differ on the optimum depth of sedation. Peroral DBEs sometimes require deep sedation or general anesthesia to avoid or control pain.^[@bibr3-2050312117729920],[@bibr18-2050312117729920]^ To avoid the gag reflex, which often causes body motions, deeper sedation may be given.

Most of the patients were satisfied with the level of sedation. However, because DEX has no amnesic action, patients often had recollection of any discomfort associated with the examination.^[@bibr19-2050312117729920]^ In fact, 15 (93.8%) of the 16 unsatisfied patients had recollection of the procedure. Amnesic action may be an advantage in patients undergoing painful surgery.^[@bibr20-2050312117729920]^ To improve patient satisfaction, the dose of benzodiazepine, which has amnesic action, should be increased.

However, this study has some limitations. First, the propensity score matching does not account for unmeasured confounders, unlike in a randomized controlled clinical trial. In this study, the propensity score was adjusted by the significant factors of each adverse event in each group. These factors were also reported by the other articles as risk factors.^[@bibr21-2050312117729920][@bibr22-2050312117729920]--[@bibr23-2050312117729920]^ However, other articles reported on other risk factors, such as diabetes, which were not significant factors in this study.^[@bibr24-2050312117729920]^

Second, there was a difference in the measurement of anesthetic depth between the MDZ and the DEX groups. Although both RSS levels 3--5 (used in the MDZ group) and BIS 60-80 are equivalent to moderate or deep sedation, there are no reports that they are equal.^[@bibr11-2050312117729920],[@bibr25-2050312117729920]^ BIS monitoring leads to higher patient and endoscopist satisfaction scores; thus, less adverse events in the DEX group might have been affected by BIS monitoring.^[@bibr26-2050312117729920]^ Finally, the criterion additional sedatives and analgesic differs between the MDZ and the DEX groups. This could have possibly led to the administration of a higher pentazocine dose in the DEX group. Sedation with DEX is effective for pain control and contributes to the lesser need for additional analgesic.^[@bibr27-2050312117729920],[@bibr28-2050312117729920]^ A higher induction dose of pentazocine had led to stronger pain control in the DEX group, which might have caused less body motions. However, the amount of pentazocine was one of the main outcomes; therefore, it was impossible to match with propensity score matching. Regarding the number of times that additional administration of drugs was required in both groups, pentazocine was given on 1.0 ± 1.1 (median 1: 0--4) times and MDZ was given on 2.6 ± 1.4 (median 3: 0--7) times in DEX group. The exact additional amount of MDZ and the number of times for additional administration of drugs in MDZ group was unknown because of retrospective review.

Conclusion {#section20-2050312117729920}
==========

DEX for conscious sedation in DBE may reduce body motion and respiratory depression compared to our previous records. Therefore, a prospective, randomized control trial using the same additional sedatives should be performed.
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